Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis
Edward Li(Sanden (Japan)), Gary H. Lyman(University of Washington), Dylan Mezzio, David L. Campbell, Kim Campbell
Cited by 19
Related Papers
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
|Journal of Clinical Oncology|2015|1k
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
|Journal of Clinical Oncology|2015|903
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
|CA A Cancer Journal for Clinicians|2015|737
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
|Journal of Clinical Oncology|2016|654